Vol 12, No 6 (2016)
Review paper
Published online: 2017-06-02
Page views 458
Article views/downloads 706
Get Citation

Connect on Social Media

Connect on Social Media

Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer

Roman Dubiański1, Agnieszka Jagiełło-Gruszfeld1, Zbigniew Nowecki1
DOI: 10.5603/OCP.2016.0017
Oncol Clin Pract 2016;12(6):209-214.

Abstract

Breast cancer remains the most frequent cancer among women in Poland with malignancies, despite significant improvement in early detection and treatment. In oestrogen receptor-positive breast cancers activation of the CDK4/CDK6/E2F axis is very common, and one of the mechanisms of action of the endocrine therapies is the suppression of CDK4 and CDK6 activity. The inhibition of CDKs is an important target for novel agents. This article concentrates on two CDK4/6 inhibitors, which showed promising efficacy in recently published studies: palbociclib and ribociclib. The phase 3 studies with palbociclib and ribociclib produced practice-changing results, improving the progression-free survival in the first-line setting in ER-positive HER2-negative advanced breast cancer when added to standard endocrine therapy.

Article available in PDF format

Purchase Subscription